Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 7/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | PRKDC | P78527 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1591899 | 0.88 | ERN1 (0.42) | ERN1ALDH1A1DGAT1PRKDCCA1 | |
| SCHEMBL16269054 | 0.84 | ERN1 (0.30) | ERN1 | |
| SCHEMBL30975524 | 0.84 | MEN1 (0.37) | ERN1ALDH1A1 | |
| SCHEMBL30169735 | 0.84 | ERN1 (0.41) | ERN1DGAT1AR | |
| SCHEMBL19209562 | 0.84 | MEN1 (0.37) | ERN1ALDH1A1 | |
| SCHEMBL23890741 | 0.84 | ERN1 (0.31) | ERN1 | |
| SCHEMBL16268831 | 0.84 | ERN1 (0.41) | ERN1DGAT1AR | |
| SCHEMBL17449171 | 0.84 | ERN1 (0.33) | ERN1PRKDCAR | |
| SCHEMBL21061499 | 0.84 | CA1 (0.33) | ERN1DGAT1CA1CA2CA9 | |
| SCHEMBL31039195 | 0.84 | ERN1 (0.33) | ERN1PRKDCAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 900 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12233052-B2 | Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2025-02-25 | — | — | US | claimed |
| CN-118005631-A | Tetrahydro-pyrido [3,4-b ] indole estrogen receptor modulators and uses thereof | 豪夫迈·罗氏有限公司 | 2024-05-10 | — | — | CN | claimed |
| CN-112375078-B | Tetrahydro-pyrido [3,4-b ] indole estrogen receptor modulators and uses thereof | 豪夫迈·罗氏有限公司 | 2023-12-19 | — | — | CN | claimed |
| US-20230045776-A9 | TETRAHYDRO- PYRIDO[3,4- b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2023-02-09 | — | — | US | claimed |
| CN-110746372-A | Small molecule acceptor material with low lowest unoccupied molecular orbital energy level, preparation method and application | 中国科学院苏州纳米技术与纳米仿生研究所南昌研究院 | 2020-02-04 | — | — | CN | claimed |
| US-9018409-B2 | Process for functionalization of unsaturated compounds | MEURICE R&D ASBL (BE) | 2015-04-28 | — | — | US | claimed |
| EP-2632886-A1 | PROCESS FOR FUNCTIONALIZATION OF UNSATURATED COMPOUNDS | Meurice R&D ASBL (BE) | 2013-09-04 | — | — | EP | claimed |
| US-20130211033-A1 | PROCESS FOR FUNCTIONALIZATION OF UNSATURATED COMPOUNDS | MEURICE R&D ASBL (BE) | 2013-08-15 | — | — | US | claimed |
| CN-101353317-B | Preparation of 4-bromo-2,6-difluorobenzonitrile | SHIJIAZHUANG GUODA IND CO LTD | 2012-07-04 | — | — | CN | claimed |
| WO-2012055946-A1 | PROCESS FOR FUNCTIONALIZATION OF UNSATURATED COMPOUNDS | MEURICE R&D ASBL (BE) | 2012-05-03 | — | — | WO | claimed |
| CN-101353317-A | Preparation of 4-bromo-2,6-difluorobenzonitrile | SHIJIAZHUANG GUODA IND CO LTD (CN) | 2009-01-28 | — | — | CN | claimed |
| US-20260138978-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | VANDERBILT UNIV (US) | 2026-05-21 | — | — | US | disclosed |
| CN-122055058-A | Biaryl compound and method for controlling plant disease | 住友化学株式会社 | 2026-05-15 | — | — | CN | disclosed |
| US-20260132139-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4739306-A2 | POLO-LIKE KINASE 1 INHIBITORS | Cervero Therapeutics, LLC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20040122057-A1 | Novel mandelic acid derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2004048335-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004031195-A1 | TRICYCLIC TETRAHYDROQUINOLINE ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-04-15 | — | — | WO | disclosed |
| US-20040006235-A1 | Process for the preparation of ring compounds | MERCK PATENT GMBH (DE) | 2004-01-08 | — | — | US | disclosed |
| EP-1346995-A1 | Process for the preparation of ring compounds | MERCK PATENT GmbH (DE) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12233052-B2 | Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof | ESR2, GPER1, ESR1 | ERN1 2602/4885ALDH1A1 1250/4885DGAT1 4533/4885 |
| US-20040006235-A1 | Process for the preparation of ring compounds | NBAS, HDHD5, DBF4 | ERN1 972/4885ALDH1A1 3474/4885DGAT1 2455/4885 |
| US-20040122057-A1 | Novel mandelic acid derivatives | F7, F11, F9 | ERN1 1226/4885ALDH1A1 519/4885DGAT1 3662/4885 |
| US-20130211033-A1 | PROCESS FOR FUNCTIONALIZATION OF UNSATURATED COMPOUNDS | F10, RPP30, PUF60 | ERN1 1728/4885ALDH1A1 46/4885DGAT1 1386/4885 |
| US-20260138978-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | CHRM1, CHRM4, CHRM2 | ERN1 2044/4885ALDH1A1 1029/4885DGAT1 1142/4885 |
| US-20260132139-A1 | HIV INHIBITOR COMPOUNDS | SLC11A2, SLC6A15, NHERF1 | ERN1 849/4885ALDH1A1 2353/4885DGAT1 4614/4885 |
| US-20230045776-A9 | TETRAHYDRO- PYRIDO[3,4- b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, GPER1, ESR1 | ERN1 2602/4885ALDH1A1 1250/4885DGAT1 4533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.